Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

NCT02605083 is registered in ClinicalTrials.gov with Effector Therapeutics as lead sponsor.

NCT NCT02605083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02605083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Lead sponsor
Effector Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
December 3, 2015
Completion date
March 22, 2019
Enrollment
66 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer